P523 - Trial Comparing Inhaled Insulin Plus Degludec Vs Usual Insulin Delivery in Adults with T1D

Technosphere Insulin (TI) is an ultra-rapid-acting inhaled insulin. This poster describes a multi-center randomized trial to evaluate the efficacy and safety of TI when used in conjunction with once-daily insulin degludec (TI-D, N=62) compared with usual care insulin delivery (UC, N=61) which included multiple daily injections (MDI), nonautomated pump, or automated insulin delivery (AID) in CGM-using adults with T1D. Following randomization, an in-clinic standardized meal (Boost nutritional shake with 37g carbs) challenge was performed. The authors present trial results including HbA1c, CGM metrics, and safety endpoints. Authors: Christopher Jacobson, PharmD, Scott Lee, MD, Kevin Codorniz, MD. Funding source: Mannkind.